Entrada Therapeutics, Inc.
TRDA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.80 | -0.07 | -0.12 |
| FCF Yield | -6.93% | 26.91% | -22.85% | -10.37% |
| EV / EBITDA | 12.83 | -1,555.63 | -4.24 | -4.87 |
| Quality | ||||
| ROIC | 9.39% | 0.54% | -36.41% | -16.73% |
| Gross Margin | 100.00% | 22.58% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.63 | -20.91 | 0.99 | 0.99 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -133.32% | 238.81% | -74.37% | -98.75% |
| Safety | ||||
| Net Debt / EBITDA | -0.89 | -1.96 | 0.20 | 5.82 |
| Interest Coverage | 0.00 | 0.00 | -36.95 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -405.64 | 4.65 | -1,153.75 | -230.70 |